BioLargo Subsidiary Clyra Medical Highlights Key Opinion Leader Presentation of Exceptional ViaCLYR(TM) Clinical Results at Leading Wound Care Symposium

Stock Information for Iron Horse Acquisitions Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Iron Horse Acquisitions Corp.

BioLargo Subsidiary Clyra Medical Signs Exclusive Distribution Agreement with Al- Hikma FZCO for ViaCLYR(TM) Across the Middle East, North Africa, and Adjacent Markets
BioLargo Signs Memorandum of Understanding with Aquatech to Accelerate Commercialization of PFAS Treatment Technology
BioLargo to Participate in a Town Hall Meeting Hosted by the BioLargo Shareholder Community on Discord on May 5, 2026
BioLargo Engineering, Science & Technologies Awarded $1.2 Million Contract to Design Pilot-Scale Minerals Processing Facility for Resource Recovery
BioLargo CEO Dennis Calvert to Present Global Environmental Leadership Award to Robert Bilott at Nassau County PFAS Forum
BioLargo Reports Annual 2025 Operating and Financial Results
BioLargo Q4 2025 and Year End Earnings Results Webcast and Conference Call on Thursday, March 5th, 2026 - 12:00 PM Eastern Time
BioLargo Subsidiary Clyra Medical Technologies Secures First Stocking Order with Advanced Solution for ViaCLYR(TM) Wound Irrigation Solution

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.